Meta-analysis finds minimal benefit of liposomal bupivacaine in TAP blocks for postoperative painLiposomal bupivacaine shows minimal benefit for postoperative pain

Frontiers in Medicine Published May 20, 2026 Study authors: Qian Cao, Rong-Mu Lin, Yan Liu, Hong-Liang Liu DOI ↗ Editorial oversight: Dr. Lars van Dijk, PhD · Surgical, Procedural & Diagnostic

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider that liposomal bupivacaine in TAP blocks provides only minimal reductions in opioid use and pain versus standard bupivacaine.

This meta-analysis pooled data from randomized controlled trials involving 1528 patients undergoing surgery who received transversus abdominis plane (TAP) blocks for postoperative analgesia. The intervention was liposomal bupivacaine, compared with standard bupivacaine (with or without adjuvants). The primary outcome was cumulative morphine milligram equivalent (MME) within 1 day after surgery.

Liposomal bupivacaine was associated with a statistically significant reduction in cumulative MME at 1 day (mean difference [MD] −0.62 mg, 95% CI −1.13 to −0.11). Pain scores on postoperative days 1–3 were also reduced (MD −0.65, −0.40, and −0.30, respectively, all with 95% CIs excluding zero). Duration of analgesia was prolonged by a mean of 5.39 hours (95% CI 0.06–10.72), and time to first flatus passage was accelerated by 0.23 days (95% CI −0.35 to −0.11).

The authors noted that the quality of evidence for these outcomes was low to very low, and they emphasized that the observed reductions were minimal. No superiority of liposomal bupivacaine over standard bupivacaine plus adjuvants was found for opioid consumption or pain relief. Large-scale RCTs are needed to validate these findings.

In practice, liposomal bupivacaine in TAP blocks may offer only marginal improvements in opioid use and pain scores. Clinicians should weigh the modest benefits against the higher cost of liposomal formulations.

This meta-analysis looked at how liposomal bupivacaine, used in transversus abdominis plane blocks, compares to standard bupivacaine for pain control after surgery. The review pooled data from studies involving 1,528 patients who had surgery and received these blocks for postoperative pain relief.

The main finding was that liposomal bupivacaine led to a small reduction in morphine use on the first day after surgery. It also showed slightly lower pain scores on the first three days and a longer time before needing more pain medicine. However, the quality of the evidence was rated as low to very low for these outcomes.

No serious safety problems were reported in the studies, but the review did not provide detailed safety data. The main reason to be careful is that the evidence is not strong, and large-scale trials are needed to confirm these small effects.

The takeaway is that liposomal bupivacaine may offer only minimal improvements in pain and opioid use compared to standard bupivacaine after surgery. Patients should discuss options with their care team.

What this means for you:

Liposomal bupivacaine may slightly reduce pain after surgery, but the benefit is small and the evidence is weak.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

This meta-analysis evaluates the efficacy of liposomal bupivacaine (LB) versus standard bupivacaine (SB), with or without adjuvants, in transversus abdominis plane (TAP) blocks for postoperative analgesia. Registered in PROSPERO (CRD420251084761), this meta-analysis screened randomized controlled trials (RCTs) published from 2000 to 2025 in PubMed, the Cochrane Library, Embase, and Wanfang databases. The primary outcome was the cumulative morphine milligram equivalent (MME) within 1 day after surgery. Secondary outcomes included the MME within 2–3 days after surgery, pain scores on postoperative days 1–3, time to first rescue analgesia, time to first flatus passage, time to first ambulation, postoperative nausea and vomiting (PONV), local anesthetic-related adverse events and toxicity, and length of hospital stay. A total of 13 randomized controlled trials (RCTs) (n = 1,528) were included in this meta-analysis. Compared to standard bupivacaine, liposomal bupivacaine reduced the MME within 1 day after surgery (mean difference (MD): −0.62 mg, 95%CI: −1.13 to −0.11). Liposomal bupivacaine also reduced pain scores on postoperative days 1–3, measured by the numeric rating scale (NRS; day 1: MD −0.65, 95% CI −1.03 to −0.28; day 2: MD −0.40, 95% CI −0.77 to −0.04; day 3: MD −0.30, 95% CI -0.48 to −0.13), prolonged the duration of analgesia (MD 5.39 h, 95% CI 0.06–10.72), and accelerated flatus passage (MD −0.23 day, 95% CI −0.35 to −0.11). No superiority of LB over SB plus adjuvants was observed in postoperative opioid consumption or pain relief. The quality of evidence was rated as low to very low for these outcomes. Liposomal bupivacaine used in TAP blocks can provide only minimal reductions in opioid consumption and pain relief after surgery compared to standard bupivacaine. Given that the quality of evidence was low to very low, large-scale RCTs are required to validate our findings.

Meta-analysis finds minimal benefit of liposomal bupivacaine in TAP blocks for postoperative painLiposomal bupivacaine shows minimal benefit for postoperative pain

Study Details

Low-intensity pulsed ultrasound shows a 0.79 healing rate in nonunion fractures across observational studies

Trial results show mixed success for ultrasound on nonunion fractures

Clinical research that matters. Delivered to your inbox.

Meta-analysis finds minimal benefit of liposomal bupivacaine in TAP blocks for postoperative painLiposomal bupivacaine shows minimal benefit for postoperative pain

More on Postoperative Pain

Study Details

Low-intensity pulsed ultrasound shows a 0.79 healing rate in nonunion fractures across observational studies

Trial results show mixed success for ultrasound on nonunion fractures

Clinical research that matters. Delivered to your inbox.

Related in Orthopedics & Sports Medicine

From Other Specialties